Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Equillium Inc (EQ)

Equillium Inc (EQ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 128,586
  • Shares Outstanding, K 24,728
  • Annual Sales, $ 0 K
  • Annual Income, $ -25,600 K
  • 60-Month Beta 2.19
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.21
Trade EQ with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.44
  • Number of Estimates 4
  • High Estimate -0.33
  • Low Estimate -0.52
  • Prior Year -0.44
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.47 +49.86%
on 11/10/20
6.44 -19.25%
on 11/11/20
-1.15 (-18.11%)
since 10/30/20
3-Month
3.47 +49.86%
on 11/10/20
7.51 -30.76%
on 10/30/20
-0.88 (-14.47%)
since 08/28/20
52-Week
2.20 +136.36%
on 03/24/20
27.05 -80.78%
on 07/13/20
+1.95 (+60.00%)
since 11/29/19

Most Recent Stories

More News
Equillium (EQ) Stalls Initiation of Phase III Study on COVID-19

Equillium (EQ) decides to not initiate a phase III study on its candidate, itolizumab, for the treatment of hospitalized COVID-19 patients at this time.

REGN : 516.03 (+0.39%)
LLY : 145.65 (-1.21%)
EQ : 5.20 (+5.69%)
VIR : 31.88 (+7.56%)
Equillium Provides Itolizumab COVID-19 Program Update

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that due to the rapidly evolving COVID-19...

EQ : 5.20 (+5.69%)
Equillium Reports Third Quarter 2020 Financial Results and Business Highlights

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced financial results for the third quarter...

EQ : 5.20 (+5.69%)
Equillium to Present at Investor Conferences in November 2020

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that Bruce Steel, Equillium's chief executive...

EQ : 5.20 (+5.69%)
Equillium to Present Data at the 2020 American College of Rheumatology Meeting Demonstrating CD6 Modulation Improves Kidney and Skin Pathology in Preclinical Models of Systemic Lupus Erythematosus

Studies further validate ongoing clinical development of itolizumab for the treatment of systemic lupus erythematosus and lupus nephritis

EQ : 5.20 (+5.69%)
Is Equillium (EQ) Stock Outpacing Its Medical Peers This Year?

Is (EQ) Outperforming Other Medical Stocks This Year?

EQ : 5.20 (+5.69%)
Stocks in play: EQ Inc.

Published an updated Research Report after EQ Works released its second quarter of 2020 financial statements. ...

EQ : 5.20 (+5.69%)
EQ Works Reports Data Revenue Continues to Grow Despite Slower COVID-19 Quarter

eResearch Corp. (www.eresearch.com) published an updated Research Report after EQ Works (TSXV: EQ ...

RAMP : 58.51 (-0.86%)
TTD : 901.07 (+3.20%)
CYPXF : 1.0500 (unch)
EQ : 5.20 (+5.69%)
Equillium Presented New Data and Insights on the CD6-ALCAM Pathway in Uncontrolled Asthma at the European Respiratory Society International Congress 2020

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that data supporting the CD6-ALCAM pathway...

EQ : 5.20 (+5.69%)
Equillium Announces Successful Completion of FDA Pre-IND Meeting Enabling Advancement of Itolizumab into a Potential Registration Study as a Treatment for Hospitalized COVID-19 Patients

Equillium anticipates filing a U.S. IND for Itolizumab for COVID-19 and initiating a global Phase 3 clinical study in Q4 2020

EQ : 5.20 (+5.69%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Equillium, Inc. is a biotechnology company. It develops products for autoimmune and inflammatory disorders. The company's product pipeline consists of EQ001 which is in clinical-stage. Equillium, Inc. is based in CA, United States.

See More

Key Turning Points

2nd Resistance Point 5.69
1st Resistance Point 5.44
Last Price 5.20
1st Support Level 4.89
2nd Support Level 4.59

See More

52-Week High 27.05
Fibonacci 61.8% 17.56
Fibonacci 50% 14.63
Fibonacci 38.2% 11.69
Last Price 5.20
52-Week Low 2.20

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar